China Universal Asset Management Co. Ltd. Has $26,000 Position in Lyell Immunopharma, Inc. $LYEL

China Universal Asset Management Co. Ltd. decreased its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 94.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,966 shares of the company’s stock after selling 55,637 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Lyell Immunopharma were worth $26,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of LYEL. Almitas Capital LLC increased its position in shares of Lyell Immunopharma by 136.3% during the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after purchasing an additional 1,432,086 shares in the last quarter. ARCH Venture Management LLC acquired a new position in Lyell Immunopharma in the second quarter valued at about $16,113,000. RBF Capital LLC bought a new stake in Lyell Immunopharma during the second quarter worth about $884,000. Nuveen LLC acquired a new stake in shares of Lyell Immunopharma during the first quarter worth approximately $345,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $159,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Monday, September 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $45.00.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $32.40 on Tuesday. The company’s 50-day moving average price is $20.23 and its two-hundred day moving average price is $14.33. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $35.15. The stock has a market capitalization of $688.18 million, a PE ratio of -1.41 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.